2013-03-14 07:02:49 -
Actelion Pharmaceuticals Ltd /
Actelion nominates Mr. John J. Greisch for election to the Board of Directors
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 14 March 2013 - Actelion Ltd (SIX: ATLN) today
issued the formal invitation to the upcoming Annual General Meeting (AGM) of
shareholders on behalf of the Board of Directors.
At the AGM the Board is nominating Mr. John J. Greisch to the Board of
Directors. Mr. Greisch is currently serving as the President and Chief Executive
Officer of Hill-Rom Holdings, Inc.
Jean-Pierre Garnier, Chairman of the Board
of Directors, commented: "As a
current CEO, John understands the challenges that face companies operating in
the current economic and business climate. I believe John's strong track record
of success in the healthcare industry will add significant practical business
acumen to Actelion's Board."
In addition, delivering on Actelion's commitment to value creation for all
stakeholders, the Board is proposing a 25% increase in the dividend payment,
increasing the payment to CHF 1.00 per share
AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2013
1. Approval of the Business Report consisting of the Annual Report, the Annual
Statutory Accounts and the Consolidated Accounts as of 31 December 2012
2. Appropriation of Available Earnings and Distribution Against Reserve from
3. Consultative Vote on Compensation Report
4. Discharge of the Board of Directors and of the Senior Management
5. Reduction of Share Capital by Cancellation of Repurchased Shares
6. Board Elections
6.1 Re-Election of Mr. Werner Henrich
6.2 Re-Election of Mr. Armin Kessler
6.3 Re-Election of Mr. Jean Malo
6.4 Election of Mr. John J. Greisch as New Board Member
7. Election of the Statutory Auditors
NOTES TO SHAREHOLDERS
The Annual General Meeting of Shareholders to approve the Business Report of the
year ending 31 December 2012 will be held on 18 April 2013 at 14.00 CEST at the
Congress Center, Messe Basel, Switzerland.
The invitation has been published in the Swiss Official Gazette of Commerce
(Schweizerisches Handelsamtsblatt) and is available, together with the company's
Annual Report, on www.actelion.com.
In order to attend and vote at the Annual General Meeting of Shareholders,
shareholders must have been registered in the Company's shareholder register by
9 April 2013 at the latest.
NOTES TO EDITORS
ABOUT MR JOHN J. GREISCH
Mr. John J. Greisch is currently President (as Executive Director) and Chief
Executive Officer of Hill-Rom Holdings, Inc., a leading medical supplier of
patient support systems such as hospital beds, therapeutic surfaces and
stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments
in research and development, introducing new smart bed technology and new
surfaces to the market as well as expanding its Singapore-based Asia-Pacific
Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter International,
Inc. in various executive positions in corporate finance, operations and general
management. From 2004-2006, he served as Chief Financial Officer and from
2006-2009 as President International Operations.
Mr Greisch earned a Bachelor's degree in Business Administration from the Miami
University, US and a Master's Degree in Management (MBA equivalent) from the
Northwestern University in Illinois, US
Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago and
is a past member of the Business School Advisory Board for Miami University's
Farmer School of Business.
ABOUT ACTELION LTD.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Founded in late 1997 Actelion is a leading player in innovative science related
to the endothelium - the single layer of cells separating every blood vessel
from the blood stream. Actelion's over 2,400 employees focus on the discovery,
development and marketing of innovative drugs for significant unmet medical
needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol:
ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
Media Release PDF:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE